NASDAQ: RTSNRetension Pharmaceuticals Inc Stock
$11.63+0.31 (+2.74%)
Updated Oct 13, 2026
RTSN Price
$11.63
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$9.66
52 Week High
$12.50
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.19
Operating Cash Flow
N/A
Beta
-97.62
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RTSN Overview
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RTSN's potential to beat the market
- RTSN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RTSN
RankedUnranked of 458
RankedUnranked of 458
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.12 | A | |
| $7.48 | A | |
| $109.62 | A |
Be the first to know about important RTSN news, forecast changes, insider trades & much more!
RTSN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RTSN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RTSN's short-term assets ($16.13M) exceed its short-term liabilities ($2.88M)
Short-term Liabilities Financials
RTSN's short-term assets ($16.13M) exceed its long-term liabilities ($0.00)
Long-term Liabilities Financials
RTSN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more RTSN due diligence checks available for Premium users.
Valuation
RTSN's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
Assets to liabilities
Assets
$16.1M
Liabilities
$2.9M
Debt to equity
-0.19
RTSN's short-term assets ($16.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RTSN's short-term assets ($16.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RTSN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RTSN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
Retension Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.